Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome

被引:291
作者
Manuelian, T
Hellwage, J
Meri, S
Caprioli, J
Noris, M
Heinen, S
Jozsi, M
Neumann, HPH
Remuzzi, G
Zipfel, PF
机构
[1] Hans Knoell Inst Nat Prod Res, Dept Infect Biol, D-07745 Jena, Germany
[2] Haartman Inst, Dept Bacteriol & Immunol, Helsinki, Finland
[3] Mario Negri Inst Pharmacol Res, I-24100 Bergamo, Italy
[4] Univ Freiburg, Dept Nephrol, Freiburg, Germany
关键词
D O I
10.1172/JCI200316651
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Hemolytic uremic syndrome (HUS) is a disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. Recent studies have identified a factor H-associated form of HUS, caused by gene mutations that cluster in the C-terminal region of the complement regulator factor H. Here we report how three mutations (E1172Stop, R1210C, and R1215G; each of the latter two identified in three independent cases from different, unrelated families) affect protein function. All three mutations cause reduced binding to the central complement component C3b/C3d to heparin, as well as to endothelial cells. These defective features of the mutant factor H proteins explain progression of endothelial cell and microvascular damage in factor H-associated genetic HUS and indicate a protective role of factor H for tissue integrity during thrombus formation.
引用
收藏
页码:1181 / 1190
页数:10
相关论文
共 40 条
[1]   Human factor H deficiency - Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism [J].
Ault, BH ;
Schmidt, BZ ;
Fowler, NL ;
Kashtan, CE ;
Ahmed, AE ;
Vogt, BA ;
Colten, HR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (40) :25168-25175
[2]  
Blackmore TK, 1998, J IMMUNOL, V160, P3342
[3]   Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome [J].
Buddles, MRH ;
Donne, RL ;
Richards, A ;
Goodship, J ;
Goodship, THJ .
AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 66 (05) :1721-1722
[4]  
Caprioli J, 2001, J AM SOC NEPHROL, V12, P297, DOI 10.1681/ASN.V122297
[5]   REGULATION OF THE ACTIVITY OF PLATELET-BOUND C-3 CONVERTASE OF THE ALTERNATIVE PATHWAY OF COMPLEMENT BY PLATELET FACTOR-H [J].
DEVINE, DV ;
ROSSE, WF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (16) :5873-5877
[6]  
DiScipio RG, 1998, J IMMUNOL, V160, P4057
[7]   Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack [J].
Fedarko, NS ;
Fohr, B ;
Robey, PG ;
Young, MF ;
Fisher, LW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (22) :16666-16672
[8]  
GORDON DL, 1995, J IMMUNOL, V155, P348
[9]  
Hindmarsh EJ, 1998, J IMMUNOL, V160, P6128
[10]  
Jokiranta TS, 2000, J BIOL CHEM, V275, P27657